How pain management practices open an account
Pain management and physical medicine practices generally open a supplier account the same way they open any clinical purchasing account: by providing the ordering physician's NPI number for verification before any pricing or product information is released. Precision Biologics verifies that NPI before an account becomes active, consistent with limiting orders to licensed professionals and physician-supervised practices.
Tampa
NPPES registry listings, primary taxonomy, retrieved 2026-10-27
253- Pain Medicine
- 118
- Physical Medicine & Rehabilitation
- 135
Documentation to request before ordering
Before adding a Wharton's jelly or exosome product to a purchasing list, most pain practices ask for the certificate of analysis, donor eligibility summary and lot release record tied to the specific lot being shipped, along with the supplier's characterization data for exosome products. These documents are made available to verified accounts rather than published, and a peer-level conversation about the documentation is available on request; that conversation addresses documentation, not clinical use, dosing or protocols.
- Certificate of analysis per lot
- Donor eligibility summary
- Lot release record
- Exosome characterization data (ELISA, NTA, SP-IRIS) where applicable
Shipping and cold-chain handling for the Southeast
Cryopreserved products are shipped overnight on dry ice in validated containers and are designed to move straight into -80 degree C storage once received. Practices receiving shipments in the Southeast typically log the lot number at intake and confirm the shipment arrived within its validated condition before transferring it to final storage. Lyophilized exosome products are shelf-stable and are handled according to the product insert included with the lot rather than a cold-chain protocol.
Verifying regulatory posture with the Florida Board of Medicine
Determining whether a specific intended use fits within the regulatory framework for a Wharton's jelly or exosome product is a decision for the treating physician and the practice's own counsel, not for a supplier. We recommend confirming your practice's standing and any applicable requirements directly with the Florida Board of Medicine.
Florida's SB 1768, in effect since July 1, 2025, permits physicians to use certain non-FDA-approved stem cell therapies in pain management under informed consent, but it is a state framework and does not alter a product's federal regulatory status. These products are not FDA approved or licensed for any disease or condition, and this page is written for licensed healthcare professionals rather than patients.
FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.
These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.
Frequently asked questions
Can a pain management practice in Tampa open a direct account?+
Yes, provided the ordering physician's NPI verifies successfully. Accounts are limited to licensed clinics, physicians and physician-supervised practices.
What exosome documentation is available for review?+
Verified accounts can request the supplier's characterization data, including ELISA, nanoparticle tracking analysis and SP-IRIS results, along with the certificate of analysis for the lot.
Does SB 1768 change what a Tampa pain practice can order from a distributor?+
No. SB 1768 addresses physician use of certain products under Florida law; it does not change how a product is regulated federally or what a distributor can represent about it. Confirm your practice's position with the Florida Board of Medicine and counsel.